Qiagen N.V. (FRA:QIA)
| Market Cap | 9.31B -4.8% |
| Revenue (ttm) | 1.76B +5.3% |
| Net Income | 345.50M +336.2% |
| EPS | 1.65 +331.3% |
| Shares Out | n/a |
| PE Ratio | 26.93 |
| Forward PE | 20.71 |
| Dividend | 2.18 (4.86%) |
| Ex-Dividend Date | Jan 8, 2026 |
| Volume | n/a |
| Average Volume | 1,565 |
| Open | 44.93 |
| Previous Close | 45.65 |
| Day's Range | 44.93 - 44.93 |
| 52-Week Range | 34.21 - 48.80 |
| Beta | n/a |
| RSI | 58.69 |
| Earnings Date | Feb 4, 2026 |
About Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]
Financial Performance
In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.
Financial numbers in USD Financial StatementsNews
Qiagen: Takeover Optionality With A High-Quality Consumables Platform
QIAGEN N.V.: QIAGEN Appoints Mark Stevenson to Supervisory Board
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand f...
QIAGEN Appoints Mark Stevenson to Supervisory Board
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for e...
QIAGEN Appoints Mark Stevenson to Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervi...
This Zoetis Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Deutsche Bank Downgrades Qiagen (QGEN) to Hold; Price Target Raised to $54 | QGEN Stock News
Deutsche Bank Downgrades Qiagen (QGEN) to Hold; Price Target Raised to $54 | QGEN Stock News
Strategy To YieldBoost QGEN To 16.3% Using Options
Shareholders of Qiagen NV (Symbol: QGEN) looking to boost their income beyond the stock's 0.5% annualized dividend yield can sell the May covered call at the $60 strike and collect the premium based o...
Qiagen Explores Possible Sale After New Buyer Talks: Report
German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges. The European molecular diagnos...
Qiagen Explores Possible Sale After New Buyer Talks: Report
German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges.
Qiagen Reaches Analyst Target Price
In recent trading, shares of Qiagen NV (Symbol: QGEN) have crossed above the average analyst 12-month target price of $53.23, changing hands for $55.45/share. When a stock reaches the target an analys...
Qiagen (QGEN) Shares Surge Amid Takeover Speculation
Qiagen (QGEN) Shares Surge Amid Takeover Speculation
Agilent, Danaher could be potential buyers of Qiagen - analyst
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports
Qiagen is weighing strategic options, including a potential sale of the diagnostics firm amid fresh takeover interest, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.
Qiagen NV (QGEN) Trading 12.78% Higher on Jan 20
Qiagen NV (QGEN) Trading 12.78% Higher on Jan 20
Qiagen (QGEN) Exploring Potential Sale Amid Market Speculation
Qiagen (QGEN) Exploring Potential Sale Amid Market Speculation
QGEN Stock Rises Amid Potential Sale Discussions
QGEN Stock Rises Amid Potential Sale Discussions
Qiagen gains on report it's weighing options amid takeover interest
Qiagen (QGEN) jumps 12% as it explores strategic options, including a sale, amid takeover interest.
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednes...
Qiagen N.V. (QGEN) Presents at German Investment Seminar 2026 - Slideshow
Qiagen N.V. (QGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Qiagen N.V. (QGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Qiagen NV at JPMorgan Healthcare Conference Transcript
Qiagen NV at JPMorgan Healthcare Conference Transcript
Qiagen (QGEN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QIAGEN N.V.: QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 QIAGEN N.V. (NYS...
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and aut...